TY - JOUR
T1 - Manhattan Vision Screening and Follow-up Study (NYC-SIGHT)
T2 - Baseline Results and Costs of a Cluster-Randomized Trial
AU - Hark, Lisa A.
AU - Horowitz, Jason D.
AU - Gorroochurn, Prakash
AU - Park, Lisa
AU - Wang, Qing
AU - Diamond, Daniel F.
AU - Harizman, Noga
AU - Auran, James D.
AU - Maruri, Stefania C.
AU - Henriquez, Desiree R.
AU - Carrion, Jailine
AU - Muhire, Remy S.Manzi
AU - Kresch, Yocheved S.
AU - Pizzi, Laura T.
AU - Jutkowitz, Eric
AU - Sapru, Saloni
AU - Sharma, Tarun
AU - De Moraes, C. Gustavo
AU - Friedman, David S.
AU - Liebmann, Jeffrey M.
AU - Cioffi, George A.
N1 - Funding Information:
Funding/Support: United States Centers for Disease Control and Prevention, Vision Health Initiative, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia (U01DP006435, U01DP006436); Research to Prevent Blindness, Inc. New York, New York. The sponsor or funding organization had no role in the design or conduct of this research. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Financial disclosure(s): The author(s) have made the following disclosure(s): All other authors have "No financial disclosures.", J.D.H.: Member Medical Policy Council of Superior Vision. R.S.M.M.: Senior Clinical Product Risk Specialist Boston Scientific. C.G.D.M.: Consultant - Carl Zeiss Meditec, Inc. Novartis Inc. Reichert, Inc. Thea Pharma, Inc.; Research grant- Carl Zeiss Meditec, Inc. NIH/NEI; Employee- Ora, Inc. D.S.F.: Research support- Genentech, Inc.; Speaking honorarium- Thea Pharmaceuticals. Chair- Data Safety Monitoring Board for Manhattan Vision Screening and Follow-Up Study. J.M.L.: Research support- NIH/NEI, Heidelberg Engineering, Novartis, Inc.; Consultant- Allergan, Inc. Genentech, Inc. Thea Pharmaceuticals, Inc. Janssen Pharma, Inc. Acknowledgments: The authors thank the CDC for funding the Manhattan Vision Screening and Follow-up Study and our project officer, Jinan Saaddine, MD, MPH for her guidance and support for the SIGHTSTUDIES. We thank our Columbia University advisors from the Wellness Center (Olajide Williams, MD), Department of Government and Community Affairs (Ross A. Frommer, Esq.), School of Nursing (Steven Ferrara, DNP, FNP-BC), Mailman School of Public Health (Linda P. Fried, MD, MPH), Internal Medicine (Rafael A. Lantigua, MD), and Occupational Therapy (Phyllis Simon, OTD, OTR/L); New York City community partners: New York City Housing Authority (NYCHA) (Marina Oteiza); NYC Department for the Aging (Lorraine Cortés-Vázquez and Edgar Yu) and DFTA Senior Center Directors; NYC Department of Health and Mental Hygiene Falls Prevention Coalition; New York Academy of Medicine; Lighthouse Guild; Vision Services for the Blind and Visually Impaired; and Volk Optical, Inc. We thank Warby Parker for providing complementary eyeglasses. We thank our Data Safety and Monitoring Board: David S. Friedman, MD, PhD, MPH (Massachusetts Eye and Ear Infirmary), Cynthia Owsley, PhD, MPH (University of Alabama at Birmingham), Jonathan S. Myers, MD (Wills Eye Hospital), Benjamin E. Leiby, PhD (Jefferson Medical College), David Weiss, PhD (Psychology Specialists of Maine), and Tarun Sharma, MD (Columbia University Ophthalmology) for advising us on the study design, clinical decision making, and evaluation of outcomes. We also thank our community health educators (Jacqueline Wright and Rachel Wint) for participating in all screenings as well as Alexa M. Kaminsky (Columbia Research Assistant) for assistance with the manuscript preparation and submission. Data Sharing Statement: All deidentified participant data, study protocol, statistical plan, and informed consent will be made available by the corresponding author upon email request. The data will be made available with investigator support after approval of a proposal and a signed data access agreement is fully executed. Study materials are available at SIGHTSTUDIES.org.
Funding Information:
Acknowledgments: The authors thank the CDC for funding the Manhattan Vision Screening and Follow-up Study and our project officer, Jinan Saaddine, MD, MPH for her guidance and support for the SIGHTSTUDIES. We thank our Columbia University advisors from the Wellness Center (Olajide Williams, MD), Department of Government and Community Affairs (Ross A. Frommer, Esq.), School of Nursing (Steven Ferrara, DNP, FNP-BC), Mailman School of Public Health (Linda P. Fried, MD, MPH), Internal Medicine (Rafael A. Lantigua, MD), and Occupational Therapy (Phyllis Simon, OTD, OTR/L); New York City community partners: New York City Housing Authority (NYCHA) (Marina Oteiza); NYC Department for the Aging (Lorraine Cortés-Vázquez and Edgar Yu) and DFTA Senior Center Directors; NYC Department of Health and Mental Hygiene Falls Prevention Coalition; New York Academy of Medicine; Lighthouse Guild; Vision Services for the Blind and Visually Impaired; and Volk Optical, Inc. We thank Warby Parker for providing complementary eyeglasses. We thank our Data Safety and Monitoring Board: David S. Friedman, MD, PhD, MPH (Massachusetts Eye and Ear Infirmary), Cynthia Owsley, PhD, MPH (University of Alabama at Birmingham), Jonathan S. Myers, MD (Wills Eye Hospital), Benjamin E. Leiby, PhD (Jefferson Medical College), David Weiss, PhD (Psychology Specialists of Maine), and Tarun Sharma, MD (Columbia University Ophthalmology) for advising us on the study design, clinical decision making, and evaluation of outcomes. We also thank our community health educators (Jacqueline Wright and Rachel Wint) for participating in all screenings as well as Alexa M. Kaminsky (Columbia Research Assistant) for assistance with the manuscript preparation and submission.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/7
Y1 - 2023/7
N2 - PURPOSE: To describe the 15-month baseline results and costs of the Manhattan Vision Screening and Follow-up Study, which aims to investigate whether innovative community-based eye health screening can improve early detection and management of glaucoma and other eye diseases among high-risk populations. DESIGN: Five-year prospective, cluster-randomized controlled trial. METHODS: Individuals aged 40+ years were recruited from public housing buildings in New York City for an eye health screening (visual acuity (VA) with correction, intraocular pressure measurements (IOP), and fundus photography). Participants with VA 20/40 or worse, IOP 23-29 mm Hg, or an unreadable fundus image failed the screening and were scheduled for an optometric examination at the same location; those with an abnormal image were referred to ophthalmology. A cost analysis was conducted alongside the study. RESULTS: A total of 708 participants were screened; mean age 68.6±11.9 years, female (65.1%), African American (51.8%) and Hispanic (42%). 78.4% (n = 555) failed the eye health screening; 35% (n= 250) had an abnormal image and were also referred to ophthalmology. 308 participants attended the optometric exam; 218 were referred to ophthalmology. Overall, 66.1% were referred to ophthalmology. The cost per participant to deliver the eye health screening and optometric examination was $180.88. The cost per case of eye disease detected was $273.64. CONCLUSIONS: This innovative study in public housing developments targeted high-risk populations, provided access to eye-care, and improved early detection of ocular diseases in New York City. The study has identified strategies to overcoming barriers to eye care to reduce eye health disparities.
AB - PURPOSE: To describe the 15-month baseline results and costs of the Manhattan Vision Screening and Follow-up Study, which aims to investigate whether innovative community-based eye health screening can improve early detection and management of glaucoma and other eye diseases among high-risk populations. DESIGN: Five-year prospective, cluster-randomized controlled trial. METHODS: Individuals aged 40+ years were recruited from public housing buildings in New York City for an eye health screening (visual acuity (VA) with correction, intraocular pressure measurements (IOP), and fundus photography). Participants with VA 20/40 or worse, IOP 23-29 mm Hg, or an unreadable fundus image failed the screening and were scheduled for an optometric examination at the same location; those with an abnormal image were referred to ophthalmology. A cost analysis was conducted alongside the study. RESULTS: A total of 708 participants were screened; mean age 68.6±11.9 years, female (65.1%), African American (51.8%) and Hispanic (42%). 78.4% (n = 555) failed the eye health screening; 35% (n= 250) had an abnormal image and were also referred to ophthalmology. 308 participants attended the optometric exam; 218 were referred to ophthalmology. Overall, 66.1% were referred to ophthalmology. The cost per participant to deliver the eye health screening and optometric examination was $180.88. The cost per case of eye disease detected was $273.64. CONCLUSIONS: This innovative study in public housing developments targeted high-risk populations, provided access to eye-care, and improved early detection of ocular diseases in New York City. The study has identified strategies to overcoming barriers to eye care to reduce eye health disparities.
UR - http://www.scopus.com/inward/record.url?scp=85151887183&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2023.01.019
DO - 10.1016/j.ajo.2023.01.019
M3 - Article
C2 - 36690289
AN - SCOPUS:85151887183
SN - 0002-9394
VL - 251
SP - 12
EP - 23
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -